Cytochromes P-450 belonging to the P-450III gene family are major Phase I enzymes present in the liver and intestinal mucosa of rats and man. There are large interindividual differences in the expression of P-450III cytochromes and it is likely that this explains, atleast in part, the interpatient variation in oral bioavailability that is characteristic of P-450III substrates such as cyclosporine A, nifedipine, ethinyl estradiol and erythromycin. Studies performed to date suggest that the regulation of the liver and intestinal P-450III cytochromes is qualitively different. The goal of the proposed research is to continue identification of the environmental and genetic factors which influence the catalytic activity of P-450III cytochromes in human liver and intestine by 1). assaying characteristics of these and 5 other human cytochromes P-450 in live r and in duodenal mucosal biopsies obtained from patients with known medication and medical histories 2). validating noninvasive assays of the catalytic activity of P-450III cytochromes in liver (intravenous erythromycin breath test and urinary excretion of 6 Beta hydroxy cortisol) and intestine (oral erythromycin breath test) by testing patients undergoing liver and/or intestinal biopsies 3). identifying the P-450III genes expressed in intestinal mucosa by using the polymerase chain reaction and isozyme-specific synthetic oligonucleotide primers 4). determining if the wide range of compounds known to induce P-450III cytochromes in rat liver also induce P-450III mRNA, protein, catalytic activity and rate of denovo synthesis in rat intestine and 5) culturing explants of rat and human small bowel mucosa to define a valid in vitro model for regulation studies. The data obtained from the continuing basic investigation of the P-450III cytochromes in rat and man are essential to understanding the important roles they are likely to play in health and disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM038149-08
Application #
3294252
Study Section
Pharmacology A Study Section (PHRA)
Project Start
1986-08-01
Project End
1994-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
8
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Jeffries, Rex E; Gamcsik, Michael P; Keshari, Kayvan R et al. (2013) Effect of oxygen concentration on viability and metabolism in a fluidized-bed bioartificial liver using ³¹P and ¹³C NMR spectroscopy. Tissue Eng Part C Methods 19:93-100
Jeffries, Rex E; Macdonald, Jeffrey M (2012) New advances in MR-compatible bioartificial liver. NMR Biomed 25:427-42
Isoherranen, Nina; Ludington, Shana R; Givens, Raymond C et al. (2008) The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos 36:146-54
Paine, Mary F; Widmer, Wilbur W; Pusek, Susan N et al. (2008) Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr 87:863-71
Leslie, Elaine M; Watkins, Paul B; Kim, Richard B et al. (2007) Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170-8
Lamba, Jatinder K; Chen, Xin; Lan, Lu-Bin et al. (2006) Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. Pharmacogenet Genomics 16:415-27
Paine, Mary F; Widmer, Wilbur W; Hart, Heather L et al. (2006) A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 83:1097-105
Paine, Mary F; Hart, Heather L; Ludington, Shana S et al. (2006) The human intestinal cytochrome P450 ""pie"". Drug Metab Dispos 34:880-6
Xu, Yang; Hashizume, Takanori; Shuhart, Margaret C et al. (2006) Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 69:56-65
Lamba, Jatinder; Strom, Stephen; Venkataramanan, Raman et al. (2006) MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 79:325-38

Showing the most recent 10 out of 48 publications